Expression Therapeutics to present at BIO CEO & Investor Conference 2022

ATLANTE, February 8, 2022 /PRNewswire/ — Expression Therapeutics, Inc. today announced that Chief Executive Officer, Dr. Mohan Raowas selected to present at the BIO CEO & Investor Conference in New York City from February 14-16 and participate in one-on-one meetings with investors.

Start February 14tha pre-recorded presentation will be available for on-demand viewing on the BIO CEO & Investor Conference portal for registered attendees and the investor slideshow is available upon request from Kim approaches at Expression Therapeutics. For more information, please see

About Expression Therapeutics, Inc.

Expression Therapeutics, Inc. is a fully integrated clinical-stage cell and gene therapy company developing novel therapies for oncology and hematology. The Company’s oncology platform is based on a proprietary signaling-free chimeric antigen receptor technology that enhances the targeting ability of gamma delta T cells and alleviates problems with long-term T cell ablation and tonic signaling to develop allogeneic cell therapies for neuroblastoma, T-cell leukemia and lymphoma and acute myeloid leukemia. Expression’s scientific breakthroughs in transgene bioengineering and protein engineering allow it to optimize its gene therapies for bleeding disorders. Expression also has a scalable, state-of-the-art 43,000 square foot manufacturing facility capable of producing cGMP viral vectors and cell therapy products to accelerate the development of the company’s clinical programs.

Kim approaches
business manager
Expression therapy
[email protected]


View original content:–investor-conference-301477632.html

SOURCE Expression Therapeutics

Comments are closed.